Cargando…

Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II/III Gliomas

Gliomas that are classified as grade II or grade III lesions by the World Health Organization (WHO) are highly aggressive, and some may develop into glioblastomas within a short period, thus portending the conferral of a poor prognosis for patients. Previous studies have implicated basement membrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhaogang, Lai, Guichuan, Sun, Lingling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602375/ https://www.ncbi.nlm.nih.gov/pubmed/36292695 http://dx.doi.org/10.3390/genes13101810

Ejemplares similares

A Bioinformatics-Based Analysis of an Anoikis-Related Gene Signature Predicts the Prognosis of Patients with Low-Grade Gliomas
por: Zhao, Songyun, et al.
Publicado: (2022)

The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas
por: Zhou, Jie, et al.
Publicado: (2022)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application
por: Karabacak, Mert, et al.
Publicado: (2023)

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas
por: Zhang, Hongbo, et al.
Publicado: (2020)

The value of basement membrane-associated genes in the prognosis and immune regulation of glioma
por: Sun, Yanqi, et al.
Publicado: (2023)

Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma
por: Wiestler, Benedikt, et al.
Publicado: (2016)

Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas
por: Luo, Cong, et al.
Publicado: (2021)

T2 mapping of molecular subtypes of WHO grade II/III gliomas
por: Kern, Maike, et al.
Publicado: (2020)

Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas
por: Lai, Guichuan, et al.
Publicado: (2022)

Development and Validation of an Immune-Related Gene Pairs Signature in Grade II/III Glioma
por: Zhang, Xu, et al.
Publicado: (2021)

Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint Inhibitors
por: Lai, Guichuan, et al.
Publicado: (2022)

Identification of Basement Membrane-Related Signatures in Gastric Cancer
por: Wang, Jinyun, et al.
Publicado: (2023)

Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer
por: Cai, Jiehui, et al.
Publicado: (2022)

Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer
por: Liu, Zhi-Yang, et al.
Publicado: (2023)

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
por: Zhang, Yu-An, et al.
Publicado: (2016)

Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas
por: Eichinger, Paul, et al.
Publicado: (2017)

Importance of evaluating health-related quality of life issues in survivors of WHO grade II or III gliomas
por: Dirven, Linda
Publicado: (2022)

Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma
por: Chen, Yanming, et al.
Publicado: (2021)

A Model for Predicting Clinical Prognosis in Patients with WHO Grade 2 Glioma
por: Gao, Qi, et al.
Publicado: (2022)

Basement membrane and blood–brain barrier
por: Xu, Lingling, et al.
Publicado: (2018)

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development
por: Binder, H., et al.
Publicado: (2019)

Epidemiological trends, relative survival, and prognosis risk factors of WHO Grade III gliomas: A population‐based study
por: Fang, Jun‐Hao, et al.
Publicado: (2019)

A newly defined basement membrane-related gene signature for the prognosis of clear-cell renal cell carcinoma
por: Zhou, Tao, et al.
Publicado: (2022)

Immune-related genes with APA in microenvironment indicate risk stratification and clinical prognosis in grade II/III gliomas
por: Xu, Shengchao, et al.
Publicado: (2021)

Predicting the prognosis of glioma by pyroptosis‐related signature
por: Chao, Bo, et al.
Publicado: (2021)

A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma
por: Liu, Wentao, et al.
Publicado: (2021)

Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC
por: Chi, Hao, et al.
Publicado: (2022)

Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas
por: Su, Jun, et al.
Publicado: (2019)

Establishment and Validation of a Ferroptosis-Related lncRNA Signature for Prognosis Prediction in Lower-Grade Glioma
por: Huang, Qian-Rong, et al.
Publicado: (2022)

Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma
por: Qiao, Qiujiang, et al.
Publicado: (2022)

Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma
por: Yu, Huihan, et al.
Publicado: (2022)

Systematic Analysis of a Pyroptosis-Related Signature to Predict the Prognosis and Immune Microenvironment of Lower-Grade Glioma
por: He, Yongze, et al.
Publicado: (2022)

MNG-03 PD-L1 EXPRESSION, PATIENT PROGNOSIS AND INITIAL WHO GRADE IN GRADE II/III MENINGIOMA
por: Kamamoto, Dai, et al.
Publicado: (2019)

Functions of RNF Family in the Tumor Microenvironment and Drugs Prediction in Grade II/III Gliomas
por: Zhang, Jingwei, et al.
Publicado: (2022)

Current therapeutic approaches to diffuse grade II and III gliomas
por: Picca, Alberto, et al.
Publicado: (2018)

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas
por: Zhang, Zhen-Yu, et al.
Publicado: (2015)

Radiation Treatment for WHO Grade II and III Meningiomas
por: Walcott, Brian P., et al.
Publicado: (2013)

Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016
por: SASAKI, Hikaru, et al.
Publicado: (2017)

A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma
por: Tao, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n857omt7s178i44155ok4h7fr5